• Home
Scientific article
English

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

ContributorsGabay, Cem; Emery, Paul; van Vollenhoven, Ronald; Dikranian, Ara; Alten, Rieke; Pavelka, Karel; Klearman, Micki; Musselman, David; Agarwal, Sunil; Green, Jennifer; Kavanaugh, Arthur
Published inLancet, vol. 381, no. 9877, p. 1541-1550
Publication date2013
Abstract

Roughly a third of patients with rheumatoid arthritis treated with biological treatments receive them as monotherapy. Tocilizumab--an inhibitor of interleukin 6 receptor signalling--has been studied as monotherapy in several clinical trials. We assessed the efficacy and safety of tocilizumab monotherapy compared with adalimumab monotherapy for patients with rheumatoid arthritis.

Keywords
  • Adult
  • Aged
  • Antibodies, Monoclonal, Humanized/therapeutic use
  • Antirheumatic Agents/therapeutic use
  • Arthritis, Rheumatoid/therapy
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
Affiliation entities
Research groups
Citation (ISO format)
GABAY, Cem et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. In: Lancet, 2013, vol. 381, n° 9877, p. 1541–1550. doi: 10.1016/S0140-6736(13)60250-0
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
Journal ISSN0140-6736
608views
0downloads

Technical informations

Creation31/07/2014 15:46:00
First validation31/07/2014 15:46:00
Update time24/01/2025 14:36:30
Status update24/01/2025 14:36:30
Last indexation24/01/2025 14:44:23
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack